NCT03757715

Brief Summary

Opioids are prescribed for moderate to severe pain disorders; however, there are contraindications and side effects that are common to all opioids. The investigators hypothesize using regional anesthetic during sinus surgery will reduce surgical pain, therefore decreasing the need for post-operative opioid medication. The primary of objective is to determine if a long-acting local regional anesthetic applied during a surgery will reduce post-operative oral opioid usage.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started May 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 27, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 29, 2018

Completed
6 months until next milestone

Study Start

First participant enrolled

May 20, 2019

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 12, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 12, 2021

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

August 31, 2022

Completed
Last Updated

August 31, 2022

Status Verified

August 1, 2022

Enrollment Period

1.8 years

First QC Date

November 27, 2018

Results QC Date

March 20, 2022

Last Update Submit

August 12, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Participant Pain Control

    Self-report of pain score on a scale of 0 to 10, with 0 being "no pain" and 10 being "worst pain imaginable"

    10 days

Secondary Outcomes (1)

  • Opioid Medication Use

    10 days

Study Arms (2)

Treatment Group

EXPERIMENTAL

20 mL of 1.3% bupivacaine with 2 mg dexamethasone injected locally in the location for sensory nerves of the sinus cavities and face during the functional endoscopic sinus surgery (FESS) procedure

Drug: BupivacaineDrug: Dexamethasone

Control Group

NO INTERVENTION

No regional anesthetic of any kind during the functional endoscopic sinus surgery (FESS) procedure

Interventions

20 mL of 1.3% bupivacaine

Also known as: Marcaine
Treatment Group

2 mg dexamethasone

Also known as: Ozurdex
Treatment Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years or older
  • Able to sign informed consent form
  • Able to comply with all study procedures and availability for the duration of the study
  • Able to speak English
  • Diagnosis of chronic rhinosinusitis
  • Scheduled to receive functional endoscopic sinus surgery (FESS) at UAB

You may not qualify if:

  • Current use of opioid medication
  • Known allergic reactions to components of the study intervention
  • History of IV drug use or abuse
  • History of opioid abuse
  • History of chronic pain disorder
  • Treatment with another investigational drug or other intervention within 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

Location

MeSH Terms

Conditions

Agnosia

Interventions

BupivacaineDexamethasoneCalcium Dobesilate

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedBenzenesulfonatesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsArylsulfonatesArylsulfonic AcidsSulfonic AcidsSulfur AcidsSulfur Compounds

Results Point of Contact

Title
Dr. Jessica W. Grayson
Organization
UAB

Study Officials

  • Brad Woodworth, MD

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 27, 2018

First Posted

November 29, 2018

Study Start

May 20, 2019

Primary Completion

March 12, 2021

Study Completion

April 12, 2021

Last Updated

August 31, 2022

Results First Posted

August 31, 2022

Record last verified: 2022-08

Locations